Lataa...
Dual HER2 blockade with lapatinib and trastuzumab in combination with chemotherapy in metastatic gastroesophageal adenocarcinoma
The development of resistance to trastuzumab in HER2‐positive gastroesophageal cancer remains a problem. The use of dual HER2 blockade to overcome this is a therapeutic strategy that should be researched more extensively.
Tallennettuna:
| Julkaisussa: | Clin Case Rep |
|---|---|
| Päätekijät: | , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
John Wiley and Sons Inc.
2021
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8077340/ https://ncbi.nlm.nih.gov/pubmed/33936677 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ccr3.4009 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|